{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=105",
    "query": {
      "intervention": "PLACEBO",
      "page": 105
    },
    "page_size": 10
  },
  "pagination": {
    "page": 105,
    "page_size": 10,
    "total_count": 33158,
    "total_pages": 3316,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=106&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=104&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T17:41:37.862Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01095796",
      "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Stribild",
          "type": "DRUG"
        },
        {
          "name": "Atripla",
          "type": "DRUG"
        },
        {
          "name": "Stribild Placebo",
          "type": "DRUG"
        },
        {
          "name": "Atripla Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 707,
      "start_date": "2010-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-11-11",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01095796"
    },
    {
      "nct_id": "NCT00795262",
      "title": "Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Quinapril (Accupril) plus Alpha Lipoic Acid",
          "type": "DRUG"
        },
        {
          "name": "accupril, placebo",
          "type": "DRUG"
        },
        {
          "name": "accupril, alpha lipoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InVasc Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 23,
      "start_date": "2008-07",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-05",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 1,
      "location_summary": "Tucker, Georgia",
      "locations": [
        {
          "city": "Tucker",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795262"
    },
    {
      "nct_id": "NCT02927262",
      "title": "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation"
      ],
      "interventions": [
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2017-01-10",
      "completion_date": "2024-02-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 6,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927262"
    },
    {
      "nct_id": "NCT03611946",
      "title": "Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose of placebo via subcutaneous injection (0.5ml).",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2018-07-06",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611946"
    },
    {
      "nct_id": "NCT02911688",
      "title": "Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Asthma"
      ],
      "interventions": [
        {
          "name": "gamma tocopherol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-09",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02911688"
    },
    {
      "nct_id": "NCT01336088",
      "title": "ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ADX48621",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 83,
      "start_date": "2011-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336088"
    },
    {
      "nct_id": "NCT02786927",
      "title": "Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo ELLIPTA device",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules for use in HANDIHALER device",
          "type": "DRUG"
        },
        {
          "name": "Inhaler Preference Questionnaire Version 1",
          "type": "OTHER"
        },
        {
          "name": "Inhaler Preference Questionnaire Version 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2016-06-21",
      "completion_date": "2016-10-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 22,
      "location_summary": "Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786927"
    },
    {
      "nct_id": "NCT02405442",
      "title": "Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 187,
      "start_date": "2015-04-30",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02405442"
    },
    {
      "nct_id": "NCT01402986",
      "title": "A Safety and Efficacy Study of Tralokinumab in Adults With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo Q2W",
          "type": "OTHER"
        },
        {
          "name": "Tralokinumab 300 mg, Q2W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Q2/4W",
          "type": "OTHER"
        },
        {
          "name": "Tralokinumab 300 mg, Q2/4W",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 689,
      "start_date": "2011-08",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 11,
      "location_summary": "Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cocoa",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01402986"
    },
    {
      "nct_id": "NCT00459173",
      "title": "Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Maintenance of Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "rimonabant (SR141716)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4850,
      "start_date": "2002-11",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2009-04-07",
      "last_synced_at": "2026-11-07T17:41:37.862Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00459173"
    }
  ]
}